Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed)
ID: 352012Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/352012

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-112.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is offering a funding opportunity titled "Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed)." This grant aims to support research that enhances the understanding of trained immunity, focusing on its mechanisms, biomarkers, and implications for immune system development, vaccine responses, and conditions such as autoimmunity and allergic diseases. The initiative is significant for advancing immunological research and public health, encouraging applications from a diverse range of eligible organizations, including higher education institutions and nonprofits. Interested applicants should note that the application deadline is June 5, 2024, with the funding opportunity closing on January 8, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-112.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-112-Full-Announcement.html
    PAR-24-112.html
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is offering a funding opportunity to enhance the understanding of "trained immunity," which refers to a non-specific immune memory in innate immune cells. The Research Project Grant (R01) aims to support projects exploring mechanisms and biomarkers of trained immunity, focusing on its implications for immune system development, vaccine responses, and conditions like autoimmunity and allergic diseases. Applications must align with NIAID's mission and are encouraged from various eligible organizations, including higher education institutions and nonprofits. Key dates include an application due date on June 5, 2024, and an expiration date for the funding opportunity on January 8, 2027. The grants do not permit clinical trials and emphasize the submission of applications through digital platforms. Review criteria will assess the project's significance, innovation, approach, and expertise of the investigators. This initiative underscores NIH's commitment to advancing immunological research and public health through rigorous scientific inquiry.
    Similar Opportunities
    Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Understanding Mechanisms and Outcomes of Trained Immunity" through the R21 grant mechanism, aimed at advancing research into innate immune memory, known as trained immunity. This initiative seeks to enhance understanding of the mechanisms, biomarkers, and functional implications of trained immunity, particularly in relation to immune system development, vaccine efficacy, and various diseases, while explicitly prohibiting clinical trials. The grant provides a maximum funding amount of $275,000, with applications accepted starting May 16, 2024, and a closing date of January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Early Immune System Development and Ontogeny" under the R01 Clinical Trial Optional grant program. This initiative aims to investigate the mechanisms of early immune development in children, particularly focusing on those with in-utero exposure to HIV or Anti-Retroviral Therapeutics (ART), and includes research on maternal and paternal immune statuses, immune cell development, and environmental influences. The program is significant for advancing laboratory research and clinical trials that enhance understanding of immune maturation in neonates and children. Eligible applicants can receive up to $400,000 per year for a maximum project duration of four years, with applications opening on April 7, 2025, and closing on January 8, 2029. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is offering a funding opportunity for investigator-initiated Resource-Related Research Projects (R24), specifically excluding clinical trials. This initiative aims to enhance existing high-priority research by supporting resources that provide critical data, materials, tools, or services beneficial to the scientific community, particularly in areas related to immunology and infectious diseases. Eligible applicants include a diverse range of institutions, such as higher education and nonprofit organizations, with proposals due by January 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-065.html.
    NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Notice of Funding Opportunity (NOFO) for the NIAID Clinical Trial Implementation Cooperative Agreement (U01), aimed at supporting high-risk clinical trials that enhance the understanding of human diseases. This funding opportunity encourages applications for investigator-initiated, milestone-driven clinical trials, with each application permitted to propose only one clinical trial that must demonstrate a hypothesis-driven approach. The initiative emphasizes the importance of mechanistic studies within clinical trials and requires a robust plan for managing trial complexity and participant safety. Interested applicants can find additional details and guidelines at the provided NIH link, with the earliest submission date set for April 12, 2024, and the application deadline on January 13, 2027. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), has announced a funding opportunity for the Clinical Trial Planning Grant (R34), aimed at supporting the planning and preparation necessary for investigator-initiated clinical trials. This grant encourages applications that focus on high-priority research aligned with NIAID's mission, providing funding of up to $150,000 for activities such as protocol development, study team establishment, and regulatory approvals. The opportunity is open to a diverse range of eligible applicants, including educational institutions, nonprofits, and governmental entities, with applications evaluated based on significance, innovation, and the research environment. Interested applicants should note that the application deadline is May 13, 2026, and can find more information at the provided NIH grants link or by contacting NIH Grants Information at grantsinfo@nih.gov.
    Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)" aimed at supporting research into the immunometabolic changes induced by HIV that may elevate the risk of tuberculosis (TB) and hepatitis B virus (HBV) in individuals on combination antiretroviral therapy (cART). This initiative seeks to fund investigator-led studies that explore the long-term effects of HIV-related alterations in immune metabolism on disease progression and treatment responses, with a focus on identifying biomarkers and innovative therapies to mitigate these risks. The grant is open to a wide range of eligible applicants, including higher education institutions, non-profits, and for-profit organizations, with no cost-sharing requirements. Interested parties should note that the application submission deadlines range from April 2025 to January 2028, and they can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For further details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-315.html.
    NIAID Research Education Program Advancing the Careers of a Diverse Research Workforce (R25 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIAID Research Education Program, aimed at advancing the careers of a diverse research workforce through educational activities. This program specifically targets individuals from underrepresented backgrounds in the biomedical and behavioral sciences, focusing on skills development courses, research experiences, and mentoring activities, while explicitly excluding clinical trials. With a funding opportunity number of PAR-23-282, applicants can request up to $351,000 annually for a maximum of five years, with the application period opening on December 26, 2023, and a submission deadline of May 25, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage for additional details.
    Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk," aimed at supporting research into the immunometabolic changes induced by HIV in individuals undergoing combination antiretroviral therapy. This initiative seeks to investigate how these alterations affect immune responses and increase the risk of subsequent infections, specifically tuberculosis (TB) and hepatitis B virus (HBV). The funding opportunity is particularly significant for advancing understanding in the field of HIV-related health risks and aims to foster innovative research approaches, including the use of machine learning and AI to identify biomarkers and therapeutic targets. Eligible applicants can receive up to $275,000 over two years, with applications due by January 7, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-316.html.
    Co-infection and Cancer (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R01 Clinical Trial Not Allowed)" aimed at enhancing the understanding of infection-related cancers, particularly the roles of co-infections with multiple pathogens, excluding HIV. This initiative seeks to investigate the mechanisms and epidemiology of cancer linked to various infectious agents, addressing significant gaps in the current understanding of cancer etiology, with a focus on health disparities in underrepresented populations. Eligible applicants include a wide range of entities such as higher education institutions, nonprofits, and foreign organizations, with no budget limit for applications, although strong preliminary data is required. Key deadlines include an earliest submission date of January 5, 2025, and a close date of January 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-082.html.
    Mucosal Immunology Studies Team (MIST) (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "Mucosal Immunology Studies Team (MIST) (U01 Clinical Trial Not Allowed)," aimed at advancing research in mucosal immunology. This initiative seeks to establish a cooperative research group focused on understanding immune mechanisms and regulation at mucosal surfaces across various tracts, including respiratory, gastrointestinal, and urogenital systems. The program is significant for fostering innovative approaches and technologies to tackle complex questions in this field. The estimated total funding for this program is $3 million, with approximately five awards expected to be made. Interested applicants, particularly small businesses with relevant expertise, are encouraged to prepare for the application process, which will open following the publication of the Notice of Funding Opportunity (NOFO) expected on July 3, 2025. For further inquiries, potential applicants can contact Dr. Deborah L. Hodge at hodged@mail.nih.gov or by phone at 240-551-3037.